Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the ana

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected i

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains

This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weig

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects,

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside i

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a not

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORK

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, wi

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other imm

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional

Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind,

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a cl

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moder

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a cl

Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for OR

Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following posi

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-

MENLO PARK, Calif. , April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq:

7,000 shares directly sold for a value of $463,000 on April 15, 2026, at a weighted average sale pri

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi